IPO Year: 2016
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/14/2026 | $80.00 | Strong Buy | Raymond James |
| 12/18/2025 | $53.00 | Outperform | Mizuho |
| 12/17/2025 | $64.00 | Buy | Citigroup |
| 9/26/2025 | $43.00 | Buy | Deutsche Bank |
| 4/8/2025 | $45.00 | Outperform | Leerink Partners |
| 3/18/2025 | $27.00 | Outperform | Wolfe Research |
| 9/4/2024 | $45.00 | Outperform | Wedbush |
| 7/16/2024 | Outperform | Evercore ISI | |
| 5/2/2024 | $50.00 | Outperform | Robert W. Baird |
| 3/1/2024 | $12.00 → $35.00 | Equal Weight → Overweight | Wells Fargo |
Fastest customizable press release news feed in the world
Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete Company reiterates expected Q3 2026 readout for rheumatoid arthritis (RA) and Q4 2026 readouts for PsA and axSpA Across SKYWAY and SKYLINE trials, planned ‘6 in '26' Phase 2 readouts enabled and on track Preclinical data supporting SPY072 in rheumatic diseases presented at 2026 European Congress of Rheumatology (EULAR) WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more compl
DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts. Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store That is why so much attention is focused on companies that are approaching pivotal readouts or are fresh off meaningful Phase 2 updates that could materially
WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare Conference – New YorkDate: Wednesday, June 3, 2026Fireside Time: 12:15 pm ET Event: Goldman Sachs 47th Annual Global Healthcare Conference – MiamiDate: Monday, June 8, 2026Fireside Time: 10:00 am ET Members of the Spyre management team will also host one-on-one investor meetings
Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Announced over-enrollment and acceleration of topline readout to the third quarter of 2026 of the rheumatoid arthritis ("RA") sub-study of the Phase 2 SKYWAY basket trial Remain on track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Further strengthened the balance sheet with $463 million gross proceeds from an underwritten public offering ofcommon stock $1.2 billion in pro forma cash, cash equivalents, and marketable securities as of March 31, 2026, with ex
WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 20,800 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on May 1, 2026 a
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced the closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 975,000 additional shares, at a public offering price per share of $62.00. The gross proceeds to Spyre from the offering were approximately $463.5 million before deducting underwriting di
WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $62.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $403.0 million, before deducting underwriting discounts and commissions and other offerin
WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase an additional $45.0 million of shares of common stock at the public offering price, less the underwrit
SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart's Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 40% and endoscopic improvement of 51% SPY001 was well tolerated with a safety profile consistent with the α4β7 class Recruitment for SKYLINE Part A closed, now enrolling Part B monotherapy and combination cohorts Management will host a conference call today at 8:00 a.m. ET WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibo
WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday, April 13, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Spyre'
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
10-Q - Spyre Therapeutics, Inc. (0001636282) (Filer)
SCHEDULE 13G - Spyre Therapeutics, Inc. (0001636282) (Subject)
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
424B5 - Spyre Therapeutics, Inc. (0001636282) (Filer)
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
DEFA14A - Spyre Therapeutics, Inc. (0001636282) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Raymond James initiated coverage of Spyre Therapeutics with a rating of Strong Buy and set a new price target of $80.00
Mizuho initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $53.00
Citigroup initiated coverage of Spyre Therapeutics with a rating of Buy and set a new price target of $64.00
Deutsche Bank initiated coverage of Spyre Therapeutics with a rating of Buy and set a new price target of $43.00
Leerink Partners initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $45.00
Wolfe Research initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $27.00
Wedbush initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $45.00
Evercore ISI initiated coverage of Spyre Therapeutics with a rating of Outperform
Robert W. Baird initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $50.00
Wells Fargo upgraded Spyre Therapeutics from Equal Weight to Overweight and set a new price target of $35.00 from $12.00 previously
This live feed shows all institutional transactions in real time.
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13G - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13G - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13D/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
Live finance-specific insights
Live Leadership Updates
SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart's Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 40% and endoscopic improvement of 51% SPY001 was well tolerated with a safety profile consistent with the α4β7 class Recruitment for SKYLINE Part A closed, now enrolling Part B monotherapy and combination cohorts Management will host a conference call today at 8:00 a.m. ET WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibo
WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday, April 13, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Spyre'
SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, more than 3-fold greater than first-generation anti-TL1A antibodies SKYLINE-UC platform study evaluating three optimized monotherapies and three potentially paradigm-changing combinations in ulcerative colitis, initiated in May 2025 SKYWAY-RD basket study evaluating SPY072 in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) announced, with initiation expected in Q3 2025 Management to host a webcast and conference call today at 8:00 a.m. ET WALTHAM, Mass., June 1
WALTHAM, Mass., June 16, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced it will report interim results from the Phase 1 SPY002 healthy volunteer trials on Tuesday, June 17, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00am ET to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Spyre's website at https://ir.spyre.com/events-and-pres
SPY001 was well tolerated with a favorable safety profile consistent with the anti-α4β7 class SPY001 pharmacokinetics exceeded expectations with a ~4-fold increase relative to vedolizumab, supporting potential Q6M maintenance dosing with a single subcutaneous (SC) injection Planned Phase 2 induction regimen targets drug concentrations in quartile 4 of vedolizumab's exposure-response relationship, which has the potential to increase or accelerate efficacy Single, lowest dose of SPY001 led to complete saturation of α4β7 receptors through Week 12 (longest follow-up available for pharmacodynamic data) Company plans to initiate a platform Phase 2 trial in mid-2025 that will include SPY001, follow
WALTHAM, Mass., Nov. 11, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced it will report interim results from the Phase 1 SPY001 healthy volunteer trial on Tuesday, November 12, 2024. Following the announcement, the Company will host a conference call and webcast at 8:00am ET to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Spyre
Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter of 2024 Presented new data on SPY003, a potential best-in-class half-life extended anti-IL-23 antibody, demonstrating robust preclinical potency and a greater than three-fold increase in non-human primate half-life compared to risankizumab Accelerated expected initiation of first-in-human trial for SPY003 to the first quarter of 2025 $414 million of cash, cash equivalents, and marketable securities as of September 30, 2024, with expected runway well into 2027, through multiple clini
WALTHAM, Mass., Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as Chief Medical Officer. Dr. Sloan brings more than 25 years of experience in both large pharmaceutical and small biotech companies with an extensive track record of program leadership in the field of Inflammation and Immunology. This includes more than 15 years
Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept data on track for year-end 2024 SPY002, an anti-TL1A antibody program designed for enhanced potency to both TL1A monomers and trimers, and extended half-life compared to existing molecules, remains on track to begin first-in-human trials in the second half of 2024 Nominated a development candidate for SPY003, a highly potent anti-IL-23 antibody with an extended half-life compared to existing molecules, with expectations to begin a first-in-human trial in the first half of 2025 $426 million of cash, cash equivalents, marketable securities
WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced the appointment of Sandra Milligan, M.D., J.D., President of Aspira Women's Health, to its Board of Directors. "With a distinguished career spanning leadership roles at large and small biopharmaceutical companies, Dr. Milligan brings deep expertise in clinical development and regulatory affairs, including within IBD, that will be invaluable as we execute o
SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous dosing successfully completed a 28-day GLP toxicity study and remains on track to begin first-in-human studies in the second quarter of 2024, with interim proof-of-concept data expected year-end 2024 SPY002, an anti-TL1A antibody designed for enhanced potency to both TL1A monomers and trimers, and extended half-life compared to existing molecules, remains on track to begin first-in-human studies in the second half of 2024 Raised $180 million in a March 2024 private placement equity financing with participation from new and existing investors $485 million of cash, cash equivalents, marketable securities, and restricted cash
Announced corporate name change to Spyre Therapeutics; appointment of Cameron Turtle, DPhil, as Chief Executive Officer; and began trading on Nasdaq under the symbol "SYRE" SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous dosing, demonstrated an updated half-life of 22 days, a greater than three-fold increase relative to vedolizumab in non-human primate pharmacokinetic data recently presented at ECCO; remains on track to begin first-in-human studies in the first half of 2024, with interim proof-of-concept data expected year-end 2024 SPY002, an anti-TL1A antibody designed for enhanced potency to both TL1A monomers and trimers, and extended half-life compared to existing m